Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen pays $71 mln to settle Enbrel, Aranesp marketing case

[Reuters] – Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotechnology company promoted its popular Enbrel and Aranesp drugs . . . → Read More: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen pays $71 mln to settle Enbrel, Aranesp marketing case Similar Articles: Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Stock Update (NASDAQ:AMGN): Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug